Clinical Trials Sponsored by Vertex Pharmaceuticals Incorporated

Total 288 results

Vertex Pharmaceuticals Incorporated

Not yet recruiting

Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and Older

Cystic Fibrosis
Vertex Pharmaceuticals Incorporated

Not yet recruiting

A Microneurography Study of NaV1.8 Inhibition in Healthy Adults

Pain
Vertex Pharmaceuticals Incorporated

Recruiting

A Study to Evaluate the Relative Bioavailability and Food Effect of a New Tablet Formulation and Strength of Suzetrigine

Pain

United States
Vertex Pharmaceuticals Incorporated

Not yet recruiting

Evaluation of Efficacy and Safety of a Single Dose of Exa-cel in Participants With Severe Sickle Cell Disease, βS/βC Genotype

Sickle Cell Disease
Vertex Pharmaceuticals Incorporated

Recruiting

Evaluation of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis (CF) Participants 12 to Less Than 24 Months of Age

Cystic Fibrosis

United Kingdom, Canada, Australia
Vertex Pharmaceuticals Incorporated

Recruiting

A Study to Evaluate Pharmacokinetics (PK) and Safety of Inaxaplin in Participants With Renal Impairment

Renal Impairment

United States
Vertex Pharmaceuticals Incorporated

Active, not recruiting

A Study To Evaluate the Relative Bioavailability, Food Effect, and Dose Proportionality of a Granule Formulation of Vanzacaftor/Tezacaftor/Deutivacaftor(VNZ/TEZ/D-IVA)

Cystic Fibrosis

United States
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate the Relative Bioavailability and Food Effect of a VX-118 Tablet Formulation

Cystic Fibrosis

United States
Vertex Pharmaceuticals Incorporated

Completed

A Study Evaluating the Long-term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis (CF) Particpants 6 Years and Older and F/MF Genotypes

Cystic Fibrosis

Canada, France, United Kingdom, Israel, Australia, Spain, Germany, Netherlands, Denmark, Switzerland
Vertex Pharmaceuticals Incorporated

Completed

Evaluation of Long-term Safety and Efficacy of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are 6 Years of Age and Older

Cystic Fibrosis

United States, Canada, Australia, Ireland, United Kingdom
Vertex Pharmaceuticals Incorporated

Completed

A Single-arm Study to Evaluate Safety and Effectiveness of VX-548 for Acute Pain

Pain

United States
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate the Effect of Food on the Pharmacokinetics of VX-548

Pain

United States
Vertex Pharmaceuticals Incorporated

Completed

Evaluation of Efficacy and Safety of VX-548 for Painful Diabetic Peripheral Neuropathy (DPN)

Diabetic Peripheral Neuropathy

United States
Vertex Pharmaceuticals Incorporated

Completed

Evaluation of the Effects of Omeprazole and Rifampin on the Pharmacokinetics of VX-548 in Healthy Participants

Pain

Australia
Vertex Pharmaceuticals Incorporated

Completed

Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy

Cystic Fibrosis

United States, Spain, Ireland, Belgium, Netherlands, United Kingdom, Australia, France, Denmark, Germany, Italy, Canada
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate the Safety of Long-term Ivacaftor Treatment in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age at Treatment Initiation and Have an Approved Ivacaftor-Responsive Mutation

Cystic Fibrosis

United States, Canada, Australia, Ireland, Germany, United Kingdom
Vertex Pharmaceuticals Incorporated

Completed

An Electrocardiogram Study to Evaluate the Effect of Vanzacaftor on the QT/QTc Interval in Healthy Participants

Cystic Fibrosis

United States
Vertex Pharmaceuticals Incorporated

Completed

A Study Evaluating the Safety of Elexacaftor/Tezacaftor/Ivacaftor in Participants With Cystic Fibrosis (CF)

Cystic Fibrosis

Spain, Belgium, Australia, Canada, Czechia
Vertex Pharmaceuticals Incorporated

Completed

Phase 2a Study of VX-147 in Adults With APOL1-mediated Focal Segmental Glomerulosclerosis

Glomerulosclerosis, Focal Segmental

United States, France, United Kingdom, Puerto Rico
Vertex Pharmaceuticals Incorporated

Completed

A Study Evaluating the Long-term Safety of VX-445 Combination Therapy

Cystic Fibrosis

United States, Spain, Ireland, Israel, Australia, United Kingdom, Germany, Canada, Denmark, Poland, Switzerland
Vertex Pharmaceuticals Incorporated

Completed

A Study Evaluating Efficacy and Safety of VX-548 for Acute Pain After an Abdominoplasty

Acute Pain

United States
Vertex Pharmaceuticals Incorporated

Completed

A Study to Explore the Impact of Lumacaftor/Ivacaftor on Disease Progression in Subjects Aged 2 Through 5 Years With Cystic Fibrosis, Homozygous for F508del

Cystic Fibrosis

Germany
Vertex Pharmaceuticals Incorporated

Completed

A Dose-ranging Study to Evaluate Efficacy and Safety of VX-150 in Subjects With Acute Pain Following Bunionectomy

Acute Pain

United States
Vertex Pharmaceuticals Incorporated

Completed

A Study Evaluating the Safety and Efficacy of VX-659 Combination Therapy in Subjects With Cystic Fibrosis

Cystic Fibrosis

United States, Israel, Ireland, United Kingdom
Vertex Pharmaceuticals Incorporated

Completed

Observational Study of Outcomes in Cystic Fibrosis Patients With Selected Gating Mutations on a CFTR Allele (The VOCAL Study) (VOCAL)

Cystic Fibrosis

Netherlands, Italy, United Kingdom
Vertex Pharmaceuticals Incorporated

Terminated

AVN944 in Combination With Gemcitabine for the Treatment of Pancreatic Cancer

Pancreatic Cancer

United States
Vertex Pharmaceuticals Incorporated

Terminated

A Safety and Efficacy Study of the Combination of VX-222 and Telaprevir in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Virus Infection

Chronic Hepatitis C Virus Infection

United States, New Zealand
Vertex Pharmaceuticals Incorporated

Terminated

Study to Evaluate the Safety and Efficacy of CTP-656 in Patients With Cystic Fibrosis With CFTR Gating Mutations

Cystic Fibrosis

United States
Vertex Pharmaceuticals Incorporated

Completed

A Rollover Safety Study of Lumacaftor/Ivacaftor in Subjects Aged 2 Years and Older With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation

Cystic Fibrosis

United States, Canada
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of VX-661/Ivacaftor in Pediatric Subjects With Cystic Fibrosis (CF)

Cystic Fibrosis

United States, Canada
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate Efficacy and Safety of TEZ/IVA in Subjects Aged 6 Through 11 Years With Cystic Fibrosis

Cystic Fibrosis

United Kingdom, France, Germany, Australia, Switzerland, Ireland, Belgium, Denmark, Poland
Vertex Pharmaceuticals Incorporated

Terminated

Evaluation of VX-659/TEZ/IVA in Cystic Fibrosis Subjects 6 Through 11 Years of Age

Cystic Fibrosis

United States
Vertex Pharmaceuticals Incorporated

Completed

A Study to Confirm the Long-term Safety and Effectiveness of Kalydeco in Patients With Cystic Fibrosis Who Have an R117H-CFTR Mutation, Including Pediatric Patients

Cystic Fibrosis
Vertex Pharmaceuticals Incorporated

Completed

A Study of VX-445 Combination Therapy in CF Subjects Homozygous for F508del (F/F)

Cystic Fibrosis

United States, Belgium, Netherlands, United Kingdom
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate Safety, Efficacy, and Tolerability of TEZ/IVA in Orkambi® (Lumacaftor/Ivacaftor) -Experienced Subjects With Cystic Fibrosis (CF)

Cystic Fibrosis

United States, France, Germany
Vertex Pharmaceuticals Incorporated

Completed

A Study of the Effects of Lumacaftor/Ivacaftor (LUM/IVA) on Exercise Tolerance in Subjects With Cystic Fibrosis (CF), Homozygous for the F508del-CFTR Mutation

Cystic Fibrosis

Australia, United Kingdom
Vertex Pharmaceuticals Incorporated

Terminated

A Study to Evaluate Efficacy and Safety of Ivacaftor in Subjects With Cystic Fibrosis Aged 3 Through 5 Years Who Have a Specified CFTR Gating Mutation

Cystic Fibrosis

United Kingdom, Canada, Australia
Vertex Pharmaceuticals Incorporated

Completed

Lumacaftor/Ivacaftor Combination Therapy in Subjects With CF Who Have an A455E CFTR Mutation

Cystic Fibrosis

Netherlands
Vertex Pharmaceuticals Incorporated

Completed

A Study Evaluating Safety and Pharmacokinetics of VX-440 in Combination With Tezacaftor/Ivacaftor in Healthy Adult Subjects

Cystic Fibrosis

United Kingdom
Vertex Pharmaceuticals Incorporated

Completed

A Phase 3 Rollover Study of Lumacaftor in Combination With Ivacaftor in Subjects 12 Years and Older With Cystic Fibrosis

Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation

United States, France, United Kingdom, Germany, Spain, Belgium, Canada, Australia, Netherlands, Denmark, Czech Republic, Italy, Austria, Ireland, Sweden
Vertex Pharmaceuticals Incorporated

Completed

A Study to Investigate VX-787 Given to Adult Volunteers Inoculated With Live Influenza Virus

Influenza Virus

United Kingdom
Vertex Pharmaceuticals Incorporated

Completed

A Safety Study for Cethrin (BA-210) in the Treatment of Acute Thoracic and Cervical Spinal Cord Injuries

Spinal Cord Injury

United States, Canada
Vertex Pharmaceuticals Incorporated

Completed

A Magnetic Resonance Imaging Study and Arthroscopic Biopsy Substudy in Subjects With Active Rheumatoid Arthritis Receiving VX-509, an Oral JAK3 Inhibitor

Rheumatoid Arthritis

United States, Denmark, Estonia, Lithuania, Netherlands, South Africa
Vertex Pharmaceuticals Incorporated

Terminated

A Study to Treat Subjects With Telaprevir, Ribavirin, and Peginterferon Who Are Coinfected With HIV and Hepatitis C Virus (HCV)

Hepatitis C

United States, Canada, Germany, Puerto Rico, Spain
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir,Peginterferon-Alfa-2a, Ribavirin) in Subjects With Chronic Hepatitis C With Compensated Cirrhosis

Chronic Hepatitis C Virus

United States, United Kingdom, Canada, Germany, Poland
Vertex Pharmaceuticals Incorporated

Completed

A Study of Telaprevir (VX-950), Pegasys and Copegus in Hepatitis C (PROVE3)

Hepatitis C

United States, Canada, Netherlands, Puerto Rico, Germany
Vertex Pharmaceuticals Incorporated

Completed

An Open-Label, Phase 1 Study in Healthy Adult Subjects to Examine the Effects of Multiple-Dose Ciprofloxacin on Ivacaftor and VX-661 in Combination With Ivacaftor

Cystic Fibrosis
Vertex Pharmaceuticals Incorporated

Completed

Study of VX-765 in Subjects With Treatment-resistant Partial Epilepsy

Partial Epilepsy

United States
Vertex Pharmaceuticals Incorporated

Completed

A Phase 1 Study to Examine the Drug-Drug Interaction of Ciprofloxacin, Itraconazole, and Rifampin on the Combination of Lumacaftor With Ivacaftor in Healthy Adult Subjects

Cystic Fibrosis

United States
Vertex Pharmaceuticals Incorporated

Completed

A Study to Assess the Relative Bioavailability Three New Formulations of Telaprevir in Healthy Subjects

Chronic Hepatitis C

United States

3

Subscribe